Oncology in Medical Technology

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 Phase II of the trial was presented in 2009 ASCO Plenary Session US Oncology, Inc . today announced that US Oncology Research will participate...

Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options

SEATTLE, June 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that a summary of the pixantrone Phase III clinical data that were presented at American Society of Clinical Oncology (ASCO) 2009 Annual Meeting on June 1, 2009 is now available at Cli...

Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting

- THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accuracy in patients whose primary cancer was 'unknown' using traditional diagnostics - SAN DIEGO, June 1 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

WAYNE, N.J., May 29 /PRNewswire/ -- Bayer Healthcare Pharmaceuticals Inc. today announced that several studies evaluating the use of Leukine(R) (sargramostim) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. "We are excited to see that several studi...

Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials

BOSTON, May 29 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL ), today announced the launch of a website designed to help investigators apply the new 1.1 version of RECIST (...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patie...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the results from a Phase I/II combination study in previously untreated patients with head and neck cancer will...

Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting

SEATTLE, May 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that data from CTI's pivotal phase III EXTEND (PIX301) trial of pixantrone in patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) will be presented at the 2009 American Soc...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2) -The First Presentation of Data on BIBF 1120 in Ovarian Cancer- RIDGEFIELD, Conn., May 14 /PRNewswire/ -- ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

- Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH - Exjade results at ASH to show benefits for chronically transfused patients by significantly reducing toxic iron that can dama...

Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma

200 Patients Enrolled in Clinical Trial to Assess Survival of Patients Receiving Litx versus Standard of Care Therapies for Unresectable Hepatocellular Carcinoma BELLEVUE, Wash., Nov. 25 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the completion of enrollment in a ...

Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer

Data Support Prognostic Value of Circulating Tumor Cells RARITAN, N.J., July 25 /PRNewswire/ -- An international, prospective clinical trial found the number of circulating tumor cells (CTCs) is a strong indicator of progression-free and overall survival among metastatic colorectal cancer pa...

Light Sciences Oncology Raises $40.1 Million in Series C Financing

Proceeds to Fund Completion of Phase III Trials of Light Infusion Therapy in Hepatocellular Carcinoma and Metastatic Colorectal Cancer and Phase I/II and Phase IIa Benign Prostatic Hyperplasia Studies BELLEVUE, Wash., July 15 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO), a priv...

Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma

Study Reports 92 Percent Response Rate to Combination Treatment FRAZER, Pa., July 15 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a phase 2 study published online today in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-c...

Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate

BELLEVUE, Wash., July 7 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced that it has begun treatment of patients with benign prostatic hyperplasia (BPH), or enlargement of the prostate, using Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment...

Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma

- Phase II Trial Shows Increase in Mature Dendritic Cells - WAYNE, N.J., June 30 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals today confirmed that results of a Phase II trial were published in the July 1 edition of the Journal of Clinical Oncology. The study showed that Leu...

ACORN Showcases Oncology CRO, EDC, PRO and Data Warehouse at 44th Annual DIA Meeting

MEMPHIS, Tenn., June 19 /PRNewswire/ -- Accelerated Community Oncology Research Network(TM) (ACORN) will be showcasing its oncology-focused CRO and research network; Guardian EDC(TM); PACE(TM) PRO System; and proprietary oncology-focused data warehouse at the 44th Annual DIA Meeting, June 22-2...

Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation

LOS ANGELES, California, June 18 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, today announced the signing of ...

Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate

ARLINGTON, Va., June 17 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has begun preclinical devel...

ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations

MEMPHIS, Tenn., June 16 /PRNewswire/ -- Accelerated Community Oncology Research Network(TM), an oncology-focused CRO and research network, announced today that its Oncology Data Warehouse has accumulated nearly 50 million data observations from over 110,000 oncology patients contained in its d...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the pr...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFactor(R), for the treatment of advanced breast cancer at the ...

Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting

PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced interim results from a Phase 1/2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in combination with radiotherapy in patients with metastatic castration resistant ...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

HOUSTON, June 2 /PRNewswire/ -- Physicians affiliated with the US Oncology Research Network are presenting the results of their clinical research at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 30 - June 3, 2008 in Chicago. Dr. Joyce O'Shaughnessy of T...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

Phase 2 Results of Perifosine in the Treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia to be presented Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a NEW YORK, June 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) toda...

New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting

WAYNE, N.J. and EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the presentation of new clinical data from the early clinical trials in the development program for Nexavar(R) (sorafenib)...

Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting

PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody. Data presented from patients with recurren...

BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting

CHICAGO, June 1 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced positive results from its Phase II clinical trial of OncoVEX GM-CSF, an oncolytic for the treatment of advanced metastat...

About 60 Clinical Studies Regarding Schering-Plough's Oncology Compounds Will be Presented at ASCO

KENILWORTH, N.J., May 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) announced today that about 80 posters, poster discussions, and oral presentations from about 60 clinical studies relating to its growing oncology franchise will be presented at the upcoming 44th Annual...

Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

BRIDGEWATER, N.J., May 29 /PRNewswire/ -- Ortho Biotech today announced that two clinical studies for DOXIL(R) (doxorubicin HCl pegylated liposome injection) will be presented at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago from May 30 to J...

Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

SEATTLE, May 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the following presentations will be made on its product Zevalin(R) (Ibritumomab Tiuxetan) and its development product OPAXIO(TM) (paclitaxel poliglumex, formerly XYOTAX(TM)) at t...

Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting

NUTLEY, N.J., May 22 /PRNewswire/ -- Roche announced today that a total of 59 U.S. and global abstracts involving its oral chemotherapy Xeloda(R) (capecitabine) have been accepted for presentation at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to...

Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer

MARSEILLE, France, May 19 /PRNewswire/ -- IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced today that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will ...

New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

BRIDGEWATER, N.J., May 16 /PRNewswire/ -- Data from three studies evaluating associations between lower mean baseline hemoglobin (Hb) levels and the rate of blood transfusions, as well as the possible effect of restrictions on reimbursement for erythropoiesis-stimulating agents (ESAs) in Medic...

BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting

WOBURN, Mass., May 16 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage products in oncology and infectious disease, announced today that the abstract describing the interim results from its Phase II clinical trial of OncoVEX GM-CSF in advanced metastatic melanoma i...

Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

MicroRNAs as Potential Biomarkers -- for Lung Cancer Diagnosis and Identification of Tumor Origin in Patients With Cancer of Unknown Primary (CUP) MicroRNAs Objectively Identify Cancer Types With High Sensitivity and Specificity and Could Revolutionize D...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- Eisai Corporation of North America announced today that results from 16 clinical data abstracts about compounds in the company's oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th A...

Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting

SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that data from an ongoing Phase 1-2 clinical trial of its novel androgen receptor antagonist, MDV3100, will be presented in an oral presentation at the 44th American Society of Clinical Oncology (...

BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting

- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors - BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data su...